Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents mixed signals. Strong revenue growth and product launches are positive, but concerns over operating losses, partner dependency, and unclear guidance on gross to net expectations for TRYNGOLZA create uncertainties. The Q&A session reveals interest in TRYNGOLZA and DAWNZERA, yet management's reluctance to comment on competitor data and gross to net expectations adds to the uncertainty. Overall, the positive elements are balanced by financial risks and unclear guidance, resulting in a neutral sentiment.
Key Financial Performance
Total Revenues (Q1 2026) $246 million, an increase of 87% compared to Q1 2025. This increase was driven by year-over-year commercial revenue growth from TRYNGOLZA and DAWNZERA and substantial R&D revenue, including approximately $95 million of milestone payments from multiple partnerships.
Commercial Revenue (Q1 2026) Increased over 42% year-over-year, driven by growth from TRYNGOLZA and DAWNZERA.
TRYNGOLZA Product Sales (Q1 2026) Over $27 million, reflecting continued strong demand offset by an anticipated decline in net price.
DAWNZERA Product Sales (Q1 2026) $16 million, an increase of 125% compared to the prior quarter.
Operating Expenses (Q1 2026) Increased 29% year-over-year, primarily driven by commercial investments supporting TRYNGOLZA and DAWNZERA and launch readiness activities for Olezarsen and Zilganersen.
Cash Balance (End of Q1 2026) Approximately $1.9 billion, reflecting the repayment of $633 million in 0% convertible notes due on April 1.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
TRYNGOLZA: Demand is growing, with a strong launch execution. It is now being launched in Europe through a partner, Sobi, expanding access for FCS patients.
DAWNZERA: Early trajectory is strong with a broad range of prescribers. It has received European approval, and launch activities have started in the region through partner Otsuka.
Olezarsen: Planned launch for severe hypertriglyceridemia (sHTG) with FDA priority review and a PDUFA date of June 30. Annual peak sales estimate increased to over $3 billion.
Zilganersen: Planned launch for Alexander's disease with FDA priority review and a PDUFA date of September 22. It is the first medicine to show disease-modifying benefits for this condition.
European market expansion: TRYNGOLZA and DAWNZERA are being launched in Europe through partnerships, expanding access to FCS and HAE patients.
Global market positioning: Ionis is preparing for five partner-led launches by the end of next year, creating a diversified revenue stream with multibillion-dollar potential.
Revenue growth: Q1 revenue increased by 87% year-over-year to $246 million, driven by TRYNGOLZA and DAWNZERA growth and milestone payments.
Expense management: Operating expenses increased by 29% year-over-year, primarily due to investments in launches and pipeline advancements.
Financial guidance improvement: 2026 revenue guidance increased to $875-$900 million, with product-level guidance provided for TRYNGOLZA ($100-$110 million) and DAWNZERA ($110-$120 million).
Pipeline diversification: Ionis is advancing a robust pipeline with multiple near- and midterm catalysts, including five partner-led launches by the end of next year.
Commercial strategy: Focus on independent launches and partnerships to maximize revenue growth and patient access.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is awaiting FDA priority reviews for Olezarsen and Zilganersen, with PDUFA dates set for June 30 and September 22, respectively. Any delays or unfavorable outcomes could impact launch timelines and revenue projections.
Pricing and Market Access Challenges: The company has adjusted the price of TRYNGOLZA to $40,000 annually, which may affect revenue in the short term and could face resistance from payers or patients.
Supply Chain and Launch Execution Risks: The company is preparing for multiple independent launches, including Olezarsen and Zilganersen. Any disruptions in supply chain or execution could delay product availability and impact revenue.
Competitive Pressures: DAWNZERA is entering a well-established market for HAE, which may slow patient transitions from legacy therapies to DAWNZERA, impacting its revenue growth.
Economic and Financial Risks: The company has projected a non-GAAP operating loss between $425 million and $475 million for 2026, which could strain financial resources if revenue targets are not met.
Partner Dependency Risks: The company relies on partners like GSK for the launch of Bepirovirsen and other partnered programs. Any delays or issues from partners could impact milestone payments and revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Olezarsen Launch and Sales Projections: Ionis is on track for the launch of Olezarsen in severe hypertriglyceridemia (sHTG) with an FDA priority review and a PDUFA date of June 30, 2026. The company has increased its annual peak sales estimate for Olezarsen from greater than $2 billion to greater than $3 billion, positioning it as a multibillion-dollar medicine and a new standard of care for sHTG.
Zilganersen Launch and Market Entry: Zilganersen, for Alexander's disease, is planned for launch in 2026. The FDA has accepted the NDA with priority review and a PDUFA date of September 22, 2026. This will be the first medicine for Alexander's disease, a rare and fatal leukodystrophy.
Partner-Led Launches and Pipeline Progress: Ionis expects five partner-led launches by the end of 2027, including Bepirovirsen for chronic hepatitis B, which has received FDA priority review with a PDUFA date of October 26, 2026. Additionally, data from two major cardiovascular outcome trials (pelacarsen Lp(a) HORIZON trial and eplontersen CARDIO-TTRansform trial) are anticipated this year.
Revenue Guidance for 2026: Ionis has improved its 2026 financial guidance, projecting total revenue between $875 million and $900 million, an increase of $75 million from prior guidance. TRYNGOLZA product sales are expected to be between $100 million and $110 million, while DAWNZERA sales are projected at $110 million to $120 million.
Commercial Expansion and Pricing Strategy: Ionis has set a new annual wholesale acquisition cost of $40,000 for TRYNGOLZA, effective April 1, 2026, applicable to both FCS and anticipated sHTG indications. The company has expanded its U.S. field organization to engage approximately 20,000 high-volume sHTG prescribers.
Neurology Portfolio and Future Commercialization: Ionis is preparing for its first independent launch from its neurology portfolio with Zilganersen. The company is building relationships with specialized HCPs, patient advocacy groups, and establishing infrastructure for diagnosis and treatment. This launch serves as a template for future rare neurology therapies.
Financial Position and Long-Term Outlook: Ionis projects a year-end cash balance of greater than $1.6 billion for 2026 and remains on track for cash flow breakeven by 2028. The company is focused on improving operating leverage and maintaining financial discipline while advancing its pipeline and commercial launches.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What enabled the increase in peak expectations for TRYNGOLZA from $2 billion to $3 billion?
A:The increase was based on completed HCP demand research, payer research, a $40,000 annual WACC price, and priority review. However, management did not comment on gross to net expectations.
Q:Is there pent-up demand for TRYNGOLZA, and what is the expected trajectory for the year?
A:There is interest in TRYNGOLZA, especially among high-risk patients. The trajectory is expected to be modest initially, with revenue guidance of $100 million to $110 million for 2026, and steady growth anticipated.
Q:How is payer access expected to ramp up for sHTG, and when will it expand to less severe patient populations?
A:Payer access will depend on the final label and review cycles, which may take 6-9 months for some payers. Expansion to less severe populations will take time as awareness and data accumulate.
Q:What are the updates on liver fat levels observed in the CORE open-label extension studies for Olezarsen?
A:Increases in liver fat were minor and transient, with no clinical sequelae. Long-term extension data show a return to baseline liver fat levels. Results will be presented in the second half of the year.
Q:How does management view competitor data in the sHTG space?
A:Management declined to comment on competitor data that does not yet exist. They emphasized the compelling Phase III data for TRYNGOLZA and expressed confidence in their $3 billion peak sales target.
Q:What feedback has been received on DAWNZERA, and what percent of patients are on every 8-week dosing?
A:Feedback has been positive, focusing on efficacy, tolerability, and convenience. Most patients start on a 4-week dosing schedule, with the option to move to 8-week dosing over time.
Q:What drove the 2026 guidance for DAWNZERA, and what is the current mix of new patient starts versus switches?
A:The guidance is based on strong Q1 performance and positive market dynamics. The majority of patients are switches from other prophylactic therapies, with some new starts from naive or acute therapy patients.
Q:What caused the decline in RANUA sales in Q1, and did the prefilled syringe option impact gross to net?
A:The decline was due to reauthorization timing early in the quarter. The prefilled syringe option is for flexibility and has not impacted gross to net.
Q:What is the status of patient identification and market size for Zilganersen?
A:Approximately 50% of the estimated 300 Alexander's disease patients in the U.S. have been identified. Efforts are ongoing to identify more patients through omnichannel campaigns.
Q:What are the quarterly dynamics for DAWNZERA, and how will they evolve in 2026 and beyond?
A:Quarterly growth is driven by patient switches, with momentum expected to continue. The $110 million to $120 million guidance reflects these dynamics.
Q:How does the potential generic entry of VYNDAMAX impact the TTR cardiomyopathy market?
A:Management believes the silencer class will become the mechanism of choice and emphasized the importance of combination usage data. They remain confident in their product's positioning and upcoming data.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on gross to net expectations for TRYNGOLZA and declined to comment on competitor data in the sHTG space.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alexander disease
DAWNZERA increase
FCS patient
FDA PDUFA
GSK
III program
Ionis multibillion
Lpa
NDA
Officer Chief
PDUFA date
RD
Sapablursen
TRYNGOLZA DAWNZERA
TRYNGOLZA FCS
Today
base
contributor
decline price
expense
hepatitis track
investment TRYNGOLZA
launch activity
launch momentum
launch sHTG
note strength
pancreatitis risk
partner launch
partnership
patient FCS
patient treatment
portfolio
priority review
relationship
review FDA
review PDUFA
sHTG Alexander
sHTG market
stream
strength balance
triglyceride pancreatitis
IONS Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript
Unknown4-29
The earnings call summary presents mixed signals. Strong revenue growth and product launches are positive, but concerns over operating losses, partner dependency, and unclear guidance on gross to net expectations for TRYNGOLZA create uncertainties. The Q&A session reveals interest in TRYNGOLZA and DAWNZERA, yet management's reluctance to comment on competitor data and gross to net expectations adds to the uncertainty. Overall, the positive elements are balanced by financial risks and unclear guidance, resulting in a neutral sentiment.
Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-9
Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
IONS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
